1Gridelli C. The ELVIS trial: A phase Ⅲ study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study [J]. Oncologist, 2001, 6 (Sup- pl 1) :4. 被引量：1
2Luciani A, Bertuzzi C, Ascione G, et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer [J]. Lung Cancer, 2009, 66 (1) : 94. 被引量：1
3Kudoh S, Takeda K, Nakagawa K, et al. Phase Ⅲ study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) [ J ]. J Clin Oncol, 2006, 24 (22):3657. 被引量：1
4LeCaer H, Barlesi F, Robinet G, et al. An open multicenter phase Ⅱ trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant eomorbidity and/or poor performance status: The GFPC 02- 02b study [J]. Lung Cancer, 2007, 57 (1):72. 被引量：1
5Tibaldi C, Bemardini I, Chella A, et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer [J]. Clin Lung Cancer, 2006, 7 (6):401. 被引量：1
6Juan O, Albert A, Campos JM, et al. Measurement and impact of co-morbidity in elderly patients with advanced non- small cell lung cancer treated with chemotherapy: A phase Ⅱ study of weekly paclitaxel [J]. Acta Oncol, 2007, 46 (3): 367. 被引量：1
7Rossi D, Dennetta D, Ugolini M, et al. Weekly paclitaxel in elderly patients ( aged > or = 70 years ) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase Ⅱ study [J]. Clin Lung Cancer, 2008, 9 (5) : 280. 被引量：1
8Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase Ⅱ trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer [J]. J Thorac Oncol, 2007, 2 (4):306. 被引量：1
9Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase Ⅱ study [J]. Lung Cancer, 2000, 27 (2) : 75. 被引量：1
10Martoni A, Di FF, Guaraldi M, et al. Prospective phase Ⅱ study of single-agent gemcitabine in untreated elderly patients with stage ⅢB/Ⅳ non-small-cell lung cancer [ J ]. Am J Clin Oncol, 2001, 24 (6):614. 被引量：1
7Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents [J] . Semin Oncol, 1999, 26 (2 Suppl 6) : 3-10. 被引量：1
8Smit EF, Mattson K, von Pawel J, et al. ALIMTA (Pemetrexed disodium) as second line treatment of non-small cell lung cancer: a phase lI study [J] . Ann Oncol, 2003, 14 (3) : 455-460. 被引量：1
9Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer [J] . J Clin Oncol, 2006, 24 (27) : 4405-4411. 被引量：1
10Vrdoljak E,Mise K, Sapunar D, et al. Survival analysis of untreated patients with non-small-cell lung cancer[ J]. Chest, 1994,106 (6) : 1797 - 1800. 被引量：1
